Michael Skynner Ph.D., B.sc. Ph.d.
Net Worth
Last updated:
What is Michael Skynner Ph.D., B.sc. Ph.d. net worth?
The estimated net worth of Dr. Michael Skynner Ph.D., B.sc. Ph.d. is at least $2,395,059 as of 3 Oct 2024. He owns shares worth $665,486 as insider, has earned $191,553 from insider trading and has received compensation worth at least $1,538,020 in Bicycle Therapeutics plc.
What is the salary of Michael Skynner Ph.D., B.sc. Ph.d.?
Dr. Michael Skynner Ph.D., B.sc. Ph.d. salary is $769,010 per year as Chief Operating Officer in Bicycle Therapeutics plc.
How old is Michael Skynner Ph.D., B.sc. Ph.d.?
Dr. Michael Skynner Ph.D., B.sc. Ph.d. is 55 years old, born in 1970.
What stocks does Michael Skynner Ph.D., B.sc. Ph.d. currently own?
As insider, Dr. Michael Skynner Ph.D., B.sc. Ph.d. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Bicycle Therapeutics plc (BCYC) | Chief Operating Officer | 92,945 | $7.16 | $665,486 |
What does Bicycle Therapeutics plc do?
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Michael Skynner Ph.D., B.sc. Ph.d. insider trading
Bicycle Therapeutics plc
Dr. Michael Skynner Ph.D., B.sc. Ph.d. has made 8 insider trades between 2023-2024, according to the Form 4 filled with the SEC. Most recently he sold 972 units of BCYC stock worth $21,637 on 3 Oct 2024.
The largest trade he's ever made was exercising 2,643 units of BCYC stock on 3 Jan 2024. As of 3 Oct 2024 he still owns at least 92,945 units of BCYC stock.
Bicycle Therapeutics key executives
Bicycle Therapeutics plc executives and other stock owners filed with the SEC:
- Dr. Dominic Smethurst M.A., M.D. (51) Chief Medical Officer
- Dr. Kevin Lee M.B.A., Ph.D. (56) Chief Executive Officer & Executive Director
- Dr. Michael Skynner Ph.D., B.sc. Ph.d. (55) Chief Operating Officer
- Dr. Nigel Crockett Ph.D. (60) Chief Bus. Officer
- Mr. Lee H. Kalowski (44) Pres & Chief Financial Officer
- Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (74) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board